Aussie Peptides · AU
PT-141 (Bremelanotide) 10mg
$89.00
Why Aussie Peptides
Lot-matched certificate
Independently analysed before release; look the lot up on the verification page.
Strictly research use
Not for human or veterinary consumption.
Express AU shipping
Discreet, fully tracked, 1–3 business days.
Aussie Peptides · specification
PT-141 (Bremelanotide) 10mg
- Presentation
- 10mg sealed glass vial
- SKU
- PT-141-10MG
- Format
- Lyophilised powder
- Purity
- ≥99% release specification by RP-HPLC — result recorded per lot
- Documentation
- Batch-specific Certificate of Analysis
- Storage
- 2–8 °C, protect from light
- Dispatch
- Cold-chain, same-day, Australia-wide
- Origin
- Packed in Australia · Aussie Peptides
- Category
- Skin & Hair
Specifications are standardised across the Aussie Peptides range. Batch values — lot number, assay result and expiry — are printed on the vial and matched to the Certificate of Analysis supplied with your order.
The Aussie Peptides label
- 1
Coral spine + hexagon mark
Every Aussie Peptides vial carries the same coral spine and molecular hexagon so a genuine vial is recognisable at a glance.
- 2
Compound, strength, fill volume
Printed in a fixed position on the cream label — compound name, strength in milligrams, and vial volume.
- 3
LOT + EXP fields
Hand-stamped per batch and matched to the Certificate of Analysis you can look up on our CoA page.
- 4
Lot-tested by RP-HPLC — research use only
The compliance line appears on every label, on every SKU, without exception.
Laboratory handling · Research peptide
Usage & handling guide
A standard lyophilised research peptide. Reconstitute gently, aliquot for single use, and keep the stock cold and dark.
- Reconstitution
- 2 mL bacteriostatic or sterile water for a standard bench stock
- Stock concentration
- ≈ 5.0 mg/mL (10 mg ÷ 2 mL)
- Storage once reconstituted
- 2–8 °C, upright, protected from light
- Stability window
- Use reconstituted stock within 14–21 days at 2–8 °C; freeze single-use aliquots at −20 °C for longer holds
1 · Equilibrate before opening
Let the sealed vial reach room temperature before breaking the seal. Opening a cold vial draws in moisture, and lyophilised peptide is hygroscopic.
2 · Add diluent down the wall
Direct the diluent slowly against the inside wall of the vial rather than onto the powder cake. A fast stream shears the peptide and lowers recovery.
3 · Dissolve, never shake
Swirl or roll gently until the cake is fully dissolved. Vortexing or shaking foams the solution and denatures peptide at the air–liquid interface.
4 · Inspect the solution
A correctly reconstituted stock is clear and free of visible particulate. Cloudiness, fibres, or a film indicates the stock should be discarded.
5 · Aliquot for single use
Split the stock into single-use aliquots in low-bind tubes and label each with compound, concentration, LOT and date. Repeated freeze–thaw is the most common cause of lost potency.
6 · Record against the CoA
Log the LOT number and the batch Certificate of Analysis reference alongside your results so every data point is traceable to a tested batch.
Figures above are worked examples for bench preparation only. Always calculate your own working concentrations from the strength printed on the vial, the exact diluent volume you added, and the batch assay result on the Certificate of Analysis.
Safety & handling cautions
- One freeze–thaw per aliquot — repeated cycling is the most common cause of lost activity.
- Always calculate working concentrations from the vial strength on the label and the exact diluent volume you added.
- Wear appropriate PPE, work in a clean and controlled area, and dispose of vials, sharps and unused stock in line with your institution’s waste procedures.
Important — no dosage advice
This guide covers reconstitution, storage and laboratory handling only. Aussie Peptides does not publish, supply or advise on human or veterinary dosing, administration schedules, or therapeutic protocols for any product, and nothing here should be interpreted as such.
All products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not medicines, are not evaluated by the TGA, and are not for human or animal consumption. Nothing on this page is medical advice — speak to a qualified healthcare professional about any health matter.
In depth
PT-141 (Bremelanotide) in Australia — research notes
PT-141 (bremelanotide) is a melanocortin receptor agonist and structural relative of Melanotan II, supplied as a 10mg lyophilised research vial with a lot-matched certificate.
- Deaminated Melanotan II metabolite
- Studied at MC3R / MC4R rather than MC1R
- 10mg lyophilised, >=99% HPLC
Melanocortin receptor research
PT-141 is the deaminated metabolite of Melanotan II and is studied primarily for MC3R and MC4R activity rather than the MC1R pigmentation pathway that dominates Melanotan II literature. Central-nervous-system signalling models are the usual research setting.
Handling
10mg reconstituted with 2mL gives 5mg/mL. Melanocortin peptides are light-sensitive in solution; keep the vial in its carton and refrigerated once reconstituted.
Comparators
Melanotan II 10mg is stocked as the direct structural comparator for laboratories separating pigmentation from central melanocortin effects. Every vial ships from our Australian storage and dispatch facility with a lot-matched certificate of analysis and cold-chain packaging.
About this compound
Research overview
PT-141 is a melanocortin receptor agonist analogue of Melanotan II, supplied as a 10mg lyophilised research vial. HPLC verified to >=99% purity with a lot-matched certificate of analysis. Laboratory research use only.
Compliance
For in‑vitro research only.
Products supplied for laboratory research. Not for human or veterinary consumption. Buyer assumes all responsibility.
Read compliance →Questions
PT-141 (Bremelanotide) 10mg — frequently asked
What is PT-141 (Bremelanotide)?+
PT-141 is a melanocortin receptor agonist analogue of Melanotan II, supplied as a 10mg lyophilised research vial. HPLC verified to >=99% purity with a lot-matched certificate of analysis. Aussie Peptides supplies PT-141 (Bremelanotide) strictly as an in-vitro laboratory reference material — it is not a therapeutic good and is not for human or veterinary use.
How pure is Aussie Peptides PT-141 (Bremelanotide)?+
Each PT-141 (Bremelanotide) lot is analysed by RP-HPLC for purity and by mass spectrometry for identity, and is released against a ≥99% purity specification. The result belongs to that lot: the number printed on your vial maps to its own Certificate of Analysis, so the figure can be recorded alongside your experimental data rather than assumed.
How is PT-141 (Bremelanotide) 10mg reconstituted and stored in the lab?+
2 mL bacteriostatic or sterile water for a standard bench stock That gives a working stock of roughly ≈ 5.0 mg/mL (10 mg ÷ 2 mL). Reconstituted vials are held at 2–8 °c, upright, protected from light, and use reconstituted stock within 14–21 days at 2–8 °c; freeze single-use aliquots at −20 °c for longer holds Sealed lyophilised 10mg vials are stable long-term at -20°C.
Is it legal to buy PT-141 (Bremelanotide) in Australia?+
PT-141 (Bremelanotide) is supplied in Australia for in-vitro laboratory research only. It is not approved by the TGA as a therapeutic good and is not sold for human or veterinary consumption. Purchasers must be 18 or over and are responsible for handling, storage and disposal under their own institutional and legal requirements.
How much is PT-141 (Bremelanotide) 10mg and how fast does it ship?+
PT-141 (Bremelanotide) 10mg is $89.00. It is in stock and dispatched same business day on orders placed before 12pm AEST. Shipping is A$12.95 express Australia-wide and free over A$199, sent discreetly packaged and fully tracked, typically 1–3 business days.
What does the research on PT-141 (Bremelanotide) investigate?+
Published work on this class focuses on collagen synthesis, copper transport, melanocortin receptor activity and dermal remodelling in laboratory models. Nothing on this page is a dosing protocol, medical advice, or a claim of therapeutic benefit — it summarises what the published literature examines.
Keep exploring
